Dependence receptors: new targets for cancer therapy

Morgan Brisset1,2, Mélodie Grandin1,2, Agnès Bernet3, Patrick Mehlen3 & Frédéric Hollande1,2,*

Abstract

Dependence receptors are known to promote survival and positive signaling such as proliferation, migration, and differentiation when activated, but to actively trigger apoptosis when unbound to their ligand. Their abnormal regulation was shown to be an important feature of tumorigenesis, allowing cancer cells to escape apoptosis triggered by these receptors while promoting in parallel major aspects of tumorigenesis such as proliferation, angiogenesis, invasiveness, and chemoresistance. This involvement in multiple cancer hallmarks has raised interest in dependence receptors as targets for cancer therapy. Although additional studies remain necessary to fully understand the complexity of signaling pathways activated by these receptors and to target them efficiently, it is now clear that dependence receptors represent very exciting targets for future cancer treatment. This manuscript reviews current knowledge on the contribution of dependence receptors to cancer and highlights the potential for therapies that activate pro-apoptotic functions of these proteins.

Keywords apoptosis; cancer hallmarks; treatment resistance; tumor progression

Subject Categories Autophagy & Cell Death; Cancer; Signal Transduction

DOI 10.15252/emmm.202114495 | Received 30 April 2021 | Revised 11 August 2021 | Accepted 11 August 2021 | Published online 20 September 2021

EMBO Mol Med (2021) 13: e14495

The dependence receptor paradigm

For a long time, the accepted paradigm regarding transmembrane receptors was solely that their activation by specific ligands could lead to the initiation of signaling cascade transduction, resulting in various outcomes such as cell proliferation, motility, or cell survival. According to this model, the absence of ligand-receptor binding was simply thought to result in the absence of intracellular signal transduction. However, the dependence receptor paradigm, first reported by Rabizadeh et al. (1993) with a study of the p75NTR receptor (Rabizadeh et al., 1993), has changed our way of understanding molecular signaling downstream from transmembrane receptors. Indeed, dependence receptors (DRs) share a common feature: They actively trigger opposite outcomes depending on the availability of their ligand. These receptors, such as classical receptors, activate positive signaling in the presence of their ligands, but they also actively trigger apoptosis in their absence (Fig 1).

To date, more than twenty DRs have been identified within structurally divergent receptor families. Simply put, their shared property is not structural but a paradoxical pro-survival/pro-cell death function. Several DRs belong to the class of tyrosine kinase receptors. Indeed, receptors such as c-MET (Tulasne et al., 2004), ALK (Mourali et al., 2006), TrkA and TrkC (Nikoletopoulou et al., 2010), RET (Bordeaux et al., 2000), EphA4 (Furne et al., 2009), EphB3 (Tsenkina et al., 2015), or even insulin receptor and insulin-like growth factor 1 receptor (Boucher et al., 2010) and more recently c-KIT (Wang et al., 2018) have been characterized as DRs. Receptors involved in major developmental signaling pathways such as hedgehog (SHH receptors patched-1) (Thibert et al., 2003) and CDON (cell adhesion associated, oncogene regulated) (Delloye-Bourgeois et al., 2013) or NOTCH (NOTCH3 receptor) are also part of this class of receptors. The p75NTR neurotrophin receptor (Rabizadeh et al., 1993), the Dickkopf-related protein 1 (DKK1) receptor Kremen1 (Caueret et al., 2016), and the GPCR receptor latrophilin (Jackson et al., 2016) also exhibit this feature. DRs also include transmembrane receptors binding netrin-1 (a laminin related protein involved in axon guidance), such as deleted in colorectal carcinoma (DCC), uncoordinated 5 homologs (UNC5H (A-D)) and neogenin (Llambi et al., 2001; Arakawa, 2004; Matsunaga et al., 2004; Mille et al., 2009), although the latter may not display any real dependence toward Netrin-1 but rather toward the repulsive guidance molecule (RGM). Finally, even some integrin subtypes such as α5β3 and α5β1 (Stupack et al., 2001; Stupack, 2005) have been shown to actively trigger apoptosis when they are unbound.

Despite their divergent structure, most DRs regulate a small number of related biological processes: neuronal development and embryonic morphogenesis. Moreover, in many cases, their ligand-dependent activation results in the stimulation of common signaling pathways, including PI3K/AKT and MAPK/ERK. These similarities may suggest that DRs act in a coordinated manner to modulate physiological functions such as neuronal development or embryonic vasculogenesis.

1 Department of Clinical Pathology, Victorian Comprehensive Cancer Centre, The University of Melbourne, Melbourne, Vic., Australia
2 University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Melbourne, Vic., Australia
3 Apoptosis, Cancer and Development Laboratory, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Centre Léon Bérard, Université de Lyon, Lyon, France
*Corresponding author: Tel: +613 8559 7023; E-mail: frederic.hollande@unimelb.edu.au

© 2021 The Authors. Published under the terms of the CC BY 4.0 license
The dependence function of DRs: ligand-independent activation of apoptotic signals

Conversely, multiple DRs also show similarities in the way they trigger apoptosis. For example, in most cases, DR monomerization in the absence of ligand appears to initiate the apoptotic cascade through activation of various pro-apoptotic protein partners (Negulescu & Mehlen, 2018). However, there are some exceptions to this paradigm. For instance, it was recently reported that withdrawal of DKK1 triggers the oligomerization of Kremen1, rather than its monomerization (Sumia et al., 2019). The next step of ligand-independent DR activation of apoptotic pathways frequently involves cleavage of an intracellular receptor moiety, a process that remains only partially understood. This initial step of DR activation appears heavily dependent on pro-apoptotic proteases, including but not restricted to caspases. In some cases, “non-apoptotic” proteases such as calpains, serine proteases, or lysosomal proteases have been shown to induce DR cleavage, with cleavage products sometimes initiating caspase-dependent downstream signaling (Huaï et al., 2010). Another mechanism appears to rely on the previously reported finding that non-apoptotic cells have a baseline level of caspase activation, which plays a role in regulating differentiation during tissue development (Svandova et al., 2018). Such level of caspase activity is insufficient to trigger apoptosis but may be sufficient to initiate DR cleavage upon ligand withdrawal (Negulescu & Mehlen, 2018), suggesting that changes in DR oligomerization and/or conformation may be sufficient for them to reach a caspase-sensitivity threshold. Accordingly, DR amino acid sequences often contain caspase-like cleavage sites juxtaposed to an aspartate (Bredesten et al., 2005), a well-known feature of caspase cleavage sites (Bratton & Cohen, 2001). Intracellular region within DR frequently exhibits unique a caspase-like cleavage site, as seen in NOTCH3, DCC, neogenin, PITCH-1, ALK, EphA4, EphB3, c-KIT, CDON, as well as in the UNC5H receptor family, while multiple cleavage sites have been reported for other DRs such as RET, MET, and TrkC (Negulescu & Mehlen, 2018; Wang et al., 2018). In contrast, integrin isoforms previously identified as DRs do not exhibit any recognized cleavage site, even though β-integrins induce apoptosis through recruitment and downstream activation of caspase-8 (Stupack et al., 2001). Similarly, no cleavage sites were identified for p75NTR, latrophilin, IR, IGF-1R, suggesting that early ligand-independent signaling downstream from these receptors may not involve their cleavage. Interestingly, caspases responsible for DR cleavages involve both “initiator” (caspases 2, 8, 9, 10, and 12) and “effector” caspases (caspases 3, 6, and 7). For instance, upon withdrawal of their respective ligand, the intracellular regions of UNC5B or c-KIT are cleaved by caspase-3, UNCSD can be cleaved by caspase-2 or 3, while EphB3 can be cleaved by caspase-8 or 9 (Abbaspour Babaei et al., 2016; Tsenkina et al., 2020; Zhu et al., 2021). Moreover, studies reveal that DCC can interact with caspase-3 or caspase-9 depending on its conformation, suggesting implication of one of these caspases in DCC cleavage (Forcet et al., 2001).

DR cleavage by caspases leads to their conformational modification, most frequently resulting in the exposure of a dependence domain of these receptors that remains anchored to the extracellular membrane. In contrast, the dependence domain of a few DRs (c-MET, RET, TrkC, c-KIT, and UNC5H receptors) is released in the cytoplasm (Bordeaux et al., 2000; Tulasne et al., 2004; Wang et al., 2018; Zhu et al., 2021). Exposure or release of dependence domains leads to the recruitment and activation of apoptotic partners, most frequently caspases. DRs such as c-KIT, DCC, RET, TrkC, CDON, Notch3, PlexinD1, or PTC-1 trigger apoptosis through activation of caspases 3 and 9, whereas p75 NTR acts through caspase 2 activation. Thus, DRs appear to play a major role in the amplification of caspase signaling. Indeed, on the one hand some level of...
pre-existing caspase activation appears required to initiate pro-
apoptotic signaling from several DRs following withdrawal of their
ligand, through cleavage of these receptors. In turn, most of these
receptors also activate caspases and thereby contribute to the emer-
gence of pro-apoptotic signaling “waves”. DRs act as an intermedi-
ate between “initiator” and “effector” caspases, and their ligand-
independent function could also synergize with other effectors to
amplify pro-apoptotic signals. An example of such positive feedback
loop involves p53 which, beyond its direct role in promoting apop-
tosis, also mediates upregulation of UNC5B and thereby leads to
enhanced sensitivity to Netrin-1 deprivation [34].

It is also noteworthy that apoptotic cascades triggered by some
DRs do not always involve downstream recruitment of caspases but
rather involve formation of pro-apoptotic complexes with various
other protein partners. The nature of recruited partners may not
correlate with receptor structure, as exemplified by the UNC5H
receptor family. Indeed, contrary to what structural homology
among members of this family may suggest, these receptors trigger
different apoptotic complexes involving distinct apoptotic partners.
For example, upon Netrin-1 withdrawal, monomerization of UNC5A
activates the c-Jun apoptotic pathway through its interaction with
the neurotrophin receptor-interacting MAGE homolog NRAGE (Wil-
liams et al, 2003). In contrast, UNC5B monomerization leads to
PP2A (protein phosphatase 2A) recruitment and to the subsequent
dehphosphorylation and activation of DAPK1 (death-associated
protein kinase 1) (Llambi et al, 2005), a mechanism inhibited by
CIP2A (cellular inhibitor of PP2A) in the presence of Netrin-1.
UNC5D is cleaved by caspases 2 or 3, and the resulting intracellular
fragment interacts with E2F1 (E2F transcription factor 1) into the
nucleus to activate transcription of pro-apoptotic genes (Zhu et al,
2013). Finally, although pro-apoptotic mechanisms downstream
from UNC5C remain less characterized, UNC5C intracellular cleav-
age by γ-secretase upon Netrin-1 deficiency has been observed in
Alzheimer disease and may also occur in other models (Chen et al,
2021).

In addition, pro-apoptotic cascades triggered by several other
DRs involve direct modulation of mitochondrial function. For exam-
ple, NT-3 withdrawal induces an internal cleavage of TrkC, followed
by translocation of the cleaved intracellular portion into mitochon-
drial membrane via the protein Cobra 1 (cofactor of BRAC1). In
turn, this leads to permeabilization of the mitochondria, release
of cytochrome C and eventually to cell death via apoptosome activa-
tion (Ichim et al, 2013). The mechanism for c-MET-induced cell
death also involves mitochondrial membrane permeabilization.
Upon HGF withdrawal, MET is cleaved to yield a 40 kD intracellular
fragment called p40MET (Foveau et al, 2007). This fragment local-
izes to mitochondria-associated membrane (MAM) regions of the
endoplasmic reticulum and triggers a calcium transfer from the
endoplasmic reticulum toward the mitochondria. Massive Ca2+
entry into the mitochondria leads to mPTP (mitochondrial permeability
transition pore) opening and to the release of mitochondrial compo-
nents that trigger cell apoptosis (Duplaquet et al, 2020). PlexinD1
interacts with the nuclear receptor NR4A1 (nuclear receptor subfam-
ily 4 group A member 1) to induce cell death through cytochrome-c
release and caspase-9 activation (Luchino et al, 2013). Finally, ALK
cleavage by caspase-3 or another caspase facilitates apoptosis,
possibly by regulating the activity of BCL-2 family members (Mourali et al., 2006).

Recent studies into mechanisms that underpin c-MET function in the absence of ligand have unraveled unexpected complexities in its regulation of cell death. First, multiple cytoplasmic cleavage products from c-MET have been described (Fernandes et al., 2019) and a 10 amino acid small c-terminal cleavage product was found to inhibit apoptosis by blocking active site of caspase-3 in hepatocytes (Ma et al., 2014). Second, the implication of c-MET in necrosis, a caspase-independent cellular death, has also been reported, with calcium stress leading to cleavage of c-MET by both ADAM-family membrane metalloproteases and calpains to generate a fragment similar to p40MET but unable to trigger apoptosis (Fernandes et al., 2019). Whether similar alternative pathways exist for other DRs to control cell death remains unanswered at this point.

Linked to their role in the regulation of apoptosis, a function for DRs in tissue homeostasis has been identified, with DR ligands being produced by cells contributing to the stem cell niche. In this context, DR signaling contributes to promoting stem cell maintenance and tissue growth when their ligand is present, but negatively regulates cell numbers through apoptotic signaling when ligand expression drops. This process can control tissue/organ size. For instance, c-MET regulates neural stem cell compartment expansion and self-renewal (Nicoleau et al., 2009), whereas Notch3 and its ligand Jagged-1 control differentiation of progenitors in the upper airways (Mori et al., 2015).

This ability of DRs to switch from positive to negative signaling is highly relevant for their function in morphogenesis, as the ability to induce cell death in the absence of ligand could be a way to foster normal organ development. However, this property of DRs can also have major pathological implications, especially in cancer. Indeed, the continuing proliferation of cancer cells may be limited by DRs, as an increasing number of cells in a growing tumor will compete for available ligand.

Collectively, these observations indicate that anomalies in the apoptotic pathways linked to DRs may confer a survival advantage to tumor cells. Accordingly, it is therefore not surprising that multiple DR pathway alterations have been reported in cancer (Fig 2), and alterations of DR signaling have been found to contribute to multiple steps in the tumorigenic process, as detailed below.

**Dependence receptors and tumorigenesis**

The negative (or apoptotic) pathway downstream from various DRs is frequently altered in cancer, thus preventing apoptosis and favoring tumor growth. For example, genes that encode DRs such as DCC, neogenin, UNCSB, UNCS, or TrkC are repressed in multiple cancer types (Bernet et al., 2007; Luo et al., 2013; Forrest et al., 2016; Kong et al., 2016; Xing et al., 2021), while cancer cells can also escape DR-mediated apoptosis through autocrine overexpression of ligands including DKK1 (Huang et al., 2014), Netrin-1 (Kefeli et al., 2017), NT-3 (Louie et al., 2013), Sema3E (Yong et al., 2016), or HGF (Baykal et al., 2003). Alternatively, cancer cells can also stimulate the secretion of dependence ligands by cancer-associated fibroblasts.
CAFs), ensuring that pro-apoptotic signaling by corresponding DRs is restrained (Sung et al., 2019).

In addition, overexpression of DRs such as PlexinD1 (Blanc et al., 2011), NOTCH3 (Park et al., 2006), c-KIT (Jones et al., 2007), c-MET (Baykal et al., 2003; Zhang et al., 2017), PTCH-1 (Kang et al., 2013), or TrkC (Jin et al., 2007) has been reported in several cancer types, in contexts where their ligands are also expressed. Indeed, joint overexpression of DRs and their ligand often promotes aggressive tumor progression, as was, for example, shown for HGF and c-MET in NSCLC (Navab et al., 2009) or gastric cancer (Toiyama et al., 2012), suggestive of a positive selection for ligand-induced rather than ligand-independent signaling. Altogether, these observations suggest that silencing of the ligand-independent pro-apoptotic DR signaling combines with “positive” ligand-driven DR signaling to confer a selective advantage to cancer cells, resulting in the promotion of multiple stages of tumorigenesis (see Fig 3 and Table 1).

**Negative selection pressure on pro-apoptotic DR signaling pathways in cancer**

In view of the pro-apoptotic activity initiated by DRs in the absence of ligand, it is somewhat unsurprising that this function, and by extension the occurrence of high receptor-to-ligand ratios that would foster the activation of ligand-independent signaling, can be negatively selected in human cancer. Indeed, prior studies have identified multiple mechanisms of DR gene genetic invalidation (as in the case of DCC in colorectal cancer) (Fearon & Vogelstein, 1990), epigenetic downregulation (e.g., for UNC5H family receptors) (Thiébault et al., 2003), or sporadic mutations leading to selective loss-of-pro-apoptotic function (e.g., for TrkC in colorectal cancer) (Ichim et al., 2013). Other mechanisms of DR pro-apoptotic pathway abrogation include the constitutive activation of positive signaling by the ALK receptor through gene fusion with EML4 (Wei et al., 2018) or the epigenetic alteration of pro-apoptotic signaling cascade proteins such as DAPK1 (apoptotic partner of UNC5B) (Grandin et al., 2016).

A causal relationship between DR inactivation and tumor progression was, for example, demonstrated in the case of UNC5C, which is downregulated via LOH and epigenetic silencing in colorectal cancer, whereby in vivo UNC5C inactivation increased tumor progression and decreased apoptosis in an APC1638N spontaneous intestinal tumors mouse model. Negative pressure on pro-apoptotic function can also result from constitutive ligand overexpression in
Ability, are essential contributors to tumor initiation and maintenance for the initiation of tumorigenesis. Cancer stem cells (CSCs), a subpopulation of cancer cells that exhibit long-term self-renewal ability, are essential contributors to tumor initiation and progression. Receptor implicated Effect on cancer cells Cancer type References

**Initiation (Stemness)**

| Ligand/Dependence receptor implicated | Sox2, c-Myc, Nanog, Klf4, Oct4 expression ALDH expression | Glioblastomas | Li, Y., et al. Proceedings of the National Academy of Sciences, 2011b. 108(24): p. 9951–9956 |
|--------------------------------------|-----------------------------------------------------------|---------------|-------------------------------------------------|
| Sox2, Nanog, Oct4 expression, hexokinase-2 expression | Pancreatic cancer | Yan, B., et al. Experimental Cell Research, 2018. 371(1): p. 63–71 |
| Netrin-1/Unc5B | CAFs secretion of pro-stemness interleukins | Colon cancer and lung cancer | Sung, P.J., et al. Cancer Res, 2019. 79(14): p. 3651–3661 |

**Promotion (Proliferation)**

| Notch3 | Cell cycle progression, Hif-2α regulation | Renal cancer | Han, Q., et al. Oncology letters, 2020. 20(6): p. 379–379 |
|---------|---------------------------------------------|--------------|--------------------------------------------------|
| P75NTR | PS3 repression | Skin, breast, bone and brain cancers | Zhou, X., et al. eLife, 2016. 5: p. e15099. |
| **Progression (Angiogenesis)**

| c-MET | PI3K pathway activation | Breast cancer | Garcia, S., et al. Int J Oncol, 2007. 31(2): p. 49–58 |
| TrkA | MMP2, NOS, VEGF expression | Breast cancer | Romon, R., et al. Molecular cancer, 2010. 9: p. 157–157 |
| ALK | VEGF, VEGFR2, MMP2, MMP9 expression | Neuroblastoma | Di Paolo, D., et al. Molecular Therapy, 2011. 19(12): p. 2201–2212 |
| c-KIT | IL-3, CXCL12, VEGFα production by mesenchymal cells | Breast cancer | Li, W., H. Xu, and C. Qian, BioMed Research International, 2017. 2017: p. 7407168 |

**Progression (EMT)**

| c-MET | MMP1, MMP2, MMP9 expression E-cadherin repression | Colon cancer | Kermorgant, S., et al. Carcinogenesis, 2001. 22(7): p. 1035–1042 |
|---------|-----------------------------------------------------|--------------|--------------------------------------------------|
| STAT3/Zeβ1 activation | Gastric cancer | Cheng, Y., et al. Translational Oncology, 2018. 11(2): p. 487–497 |
| Unc5B/Neogenin | MAPK pathway activation | Medulloblastoma | Akino, T., et al. Cancer Research, 2014. 74(14): p. 3716–3726 |
| Neogenin | Zeβ1 upregulation, PI3K/Akt activation | Gastric cancer | Qu, H., H. Sun, and X. Wang, Cellular Physiology and Biochemistry, 2018. 48(4): p. 1457–1467 |
| P75NTR | MMP12 and cadherin-11 upregulation | Glioblastomas | Berghoff, J., et al. Molecular and Cellular Neuroscience, 2015. 69: p. 41–53 |

**Chemo- and immune resistance**

| c-MET | ALDH expression | Glioblastomas | Li, Y., et al. Proceedings of the National Academy of Sciences, 2011b. 108(24): p. 9951–9956 |
| P75NTR | Mitotical quiescence | Esophageal squamous cell carcinoma | Yamaguchi, T., et al. Int J Oncol, 2016. 48(5): p. 1943–1954 |
| Notch3 | ATP-binding cassette expression | Ovarian cancer | Park, J.T., et al. The American journal of pathology, 2010. 177(5): p. 1087–1094 |
| PD-L1 expression | Breast cancer | Fatmah, A., et al. OncolImmunology, 9.1. https://doi.org/10.1080/2162402X.2020.1729299 |

### Role of DRs in tumor initiation

Activation of these receptors may provide a facilitating environment for the initiation of tumorigenesis. Cancer stem cells (CSCs), a subpopulation of cancer cells that exhibit long-term self-renewal ability, are essential contributors to tumor initiation and maintenance of tumor growth (Prasetyani & Medema, 2017), and a plethora of studies demonstrates the importance of DR activation in promoting their stem-like cell behavior. For instance, c-MET plays an important role in maintaining stemness in pancreatic cancer cells (Li et al, 2011a). Its activation results in enhanced expression of pluripotency markers NANOG, OCT4, and SOX2, through activation of YAP and potentiation of the Warburg effect (Yan et al, 2018). In fact, the activation of multiple DRs has been
shown to regulate the expression of pluripotency markers. For example, in ovarian cancer, the activation of c-KIT enhances tumor initiation in vivo through activation of PI3K/AKT and Wnt/β-catenin/TCR pathways. The crosstalk between cancer cells and cells from their microenvironment, such as cancer-associated fibroblasts (CAFs), also promotes plasticity and self-renewal through DR activation. For instance, in colon and lung cancers, cancer-associated fibroblasts (CAFs) secrete Netrin-1 and take part in a two-way signaling process with cancer cells, which involve the secretion of stemness-promoting cytokines such as interleukin-6 (IL-6), resulting in an increased stemness phenotype of cancer cells (Sung et al., 2019). These studies and multiple others (Huang et al., 2009; Park et al., 2010; Kimura et al., 2011; Li et al., 2011b; Xu et al., 2020) highlight the involvement of DRs in tumor initiation through the regulation of pluripotency markers, metabolic enzymes, and other important features of CSCs.

**DR contribution to tumor progression**

Tumor promotion involves a phase of clonal expansion. During this step, tumor cells undergo sequential genetic modifications that drive malignant transformation and enable escape from tumor suppressors. Therefore, during this step of tumorigenesis, a prevalent aspect is proliferation of tumor cells, and DR activation has major implications in the promotion of this hallmark. Thus, NOTCH3 was shown to promote the proliferation of renal cancer cells through regulation of cell cycle progression and of hypoxia-inducible transcription factor 2-alpha (HIF-2α) expression (Han et al., 2020). Another example is p75NTR activation, which enhances the clonogenic capabilities of cancer cells by inactivating p53 through activation of MDM2-mediated ubiquitylation (Zhou et al., 2016). These are representative illustrations of the combined DR involvement in promoting proliferation and escaping tumor suppressor gene-driven apoptosis, supporting transformation of a preneoplastic lesion into a malignant one and subsequently promoting tumorigenesis.

Angiogenesis constitutes another major aspect of tumor progression. The formation and remodeling of new blood vessels and capillaries are essential to compensate the tumor core hypoxia that often accompanies uncontrolled proliferation of cancer cells. Pathways triggered by DRs are critical for different aspects of angiogenesis modulation, including the secretion of vasculogenesis-promoting cytokines, of protein involved in extracellular matrix remodeling such as matrix metalloproteinases (MMPs), and in the expression of vascular growth factors such as VEGF and its receptors. These factors can be produced by cancer cells themselves, as exemplified by the secretion of several MMPs and of VEGF in neuroblastoma cells expressing ALK (Di Paolo et al., 2011). They can also be secreted by endothelial cells surrounding the tumor, as demonstrated by the increased levels of MMP2, NOS, and VEGF in endothelial cells following activation of signaling pathways such as PI3K and ERK downstream of NGF-activated TrkA, leading to enhanced invasion, cord formation, and monolayer permeability in a breast cancer model (Romon et al., 2010). Interestingly, Netrin-1 can also function as a survival factor for endothelial cells by blocking UNC5B apoptotic activity. Thus, Netrin-1 not only promotes tumor proliferation directly but may also enhance the development and survival of new vessels within the tumor (Mehlen & Guenebeaud, 2010). Moreover, Netrin-1 also plays a role in vasculogenic mimicry (VM) (Zhang et al., 2018). Importantly, VM and neo-angiogenesis promote metastatic spread, as newly formed vessels provide a route by which tumor cells can leave the primary tumor site and invade other sites in the body (Folkman, 2002; Takeda et al., 2002).

**Involvement of DRs in metastasis development**

The development of distant metastases is a key feature of aggressive tumor progression and has important implications for patient outcome. Multiple studies report the role of dual signaling from DRs in regulating the metastatic spread of tumor cells, with DR-related cell death hindering tumor cell migration to and colonization of sites where ligands are absent, and overexpression of DR ligands conversely providing a selective advantage during metastasis development. It follows that escaping DR-induced apoptotic death is an important step to foster metastatic dissemination of tumor cells as well as their survival at metastatic sites. For instance, the overexpression of Netrin-1 was reported to confer a survival advantage to metastatic cells, acting through the inhibition of DCC and UNC5H receptors apoptotic activities. This likely explains why Netrin-1 is overexpressed in metastatic breast cancer whereas its expression in non-metastatic tumors is lower (Fitamant et al., 2008). Similarly, co-expression of c-MET and its ligand HGF was shown to predict peritoneal dissemination in gastric cancer (Toiyama et al., 2012).

Besides the previously discussed role of angiogenesis as a facilitator of metastatic dissemination, tumor cells themselves often undergo a phenotypic switch that enables them to acquire invading capacities. Indeed, epithelial-to-mesenchymal transition (EMT), a well-described phenotypic switch involved in metastasis development, is one of the fields where DR regulation has been the most studied across various cancer types. DR-driven activation of PI3K and ERK pathways activates critical EMT transcription factors such as ZEB, TWIST, and SNAIL. For instance, the activation of TrkA in head and neck carcinomas activates STAT3, which in turn increases the expression of Twist1, Snai1, and Snai2, thereafter leading to decreased E-cadherin expression and increased levels of vimentin and N-cadherin (Lin et al., 2020). These transmembrane and cytoskeleton proteins are major regulators of cellular adherence and morphology, and their modulation is an essential step in the EMT process. Moreover, DRs also contribute to the metastasis process by modulating extracellular matrix composition through increased secretion of MMPs, as mentioned earlier, thus facilitating migration of cells. An additional example is the activation of c-MET receptors by HGF, which results in enhanced production by cancer cells of MMP1, MMP2, and MMP9, enzymes that can degrade extracellular matrix proteins. In addition to its effects on E-cadherin and MMPs, it has been found that c-MET regulates EMT in cancer cells through the activation of hBVR (human biliverdin reductase), an ERK nuclear transporter required for MAPK signaling (Lerner-Marmarosh et al., 2008; Liu et al., 2017). This impact of c-MET on EMT has a drastic impact on cancer cell invasiveness and metastatic abilities, and is reflected in the upregulation of both c-MET and HGF in circulating tumor cells (CTCs), as shown, for example, in hepatocellular carcinoma (Ogunwobi et al., 2013). In addition, EMT has been linked to increased chemotherapeutic resistance of cancer cells through enhancing of cancer cell survival, cell fate transition, and upregulation of drug resistance-related genes (Wang et al., 2016), suggesting that DRs may have a role in regulating this process.
**DRs and treatment response**

Indeed, numerous studies show a link between the expression of DRs in cancer cells and resistance to different types of treatments. Correlations between expression of c-MET and resistance to cisplatin and ionizing radiations in several types of cancer (De Bacco et al., 2011; Sun & Wang, 2011), or between NOTCH3 expression and enhanced cisplatin resistance (Park et al., 2010), are good illustrations of their implications. This role may directly result from their effect on cell cycle and on the expression of detoxifying enzymes such as aldehyde dehydrogenase (ALDH) and ATP-binding cassette (ABC) transporters, transmembrane proteins that mediate drug export out of the cell (Park et al., 2010; Liu et al., 2018; Prager et al., 2019). Another reason underlying the correlation between DR expression and resistance to chemotherapies could be the positive impact of these receptors on angiogenesis, since high vascular density was shown to associate with a decreased response to chemotherapies (Mattern, 2001).

**A role for DRs in immune escape?**

In addition, besides resistance to chemotherapies, DRs may also be implicated in the ability of tumor cells to escape immune surveillance in several cancer types. The correlation between NOTCH3 and PD-L1 expression in breast cancer, and especially in breast cancer stem cells, is a good illustration of this. Indeed, PD-L1 expression is modulated by NOTCH3 via the activation of mTOR signaling (Mansour et al., 2020). In addition, DRs have a significant impact on the migration and maturation of immune cells. For instance, neogenin has been described as an important regulator of neutrophil migration and an activator of inflammation in a lung injury model (Mirakaj et al., 2012). In the context of cancer, the activation of NGF-TrkA signaling axis is an important step to produce IL-10 in tumor-associated macrophages (TAMs) (Ley et al., 2013). These examples among others illustrate the modulatory effect of DRs on immune cells and their involvement in tumor immune escape.

Thus, from tumor initiation to the promotion of metastasis development and the avoidance of immune cell regulation, DRs display multiple implications along multiple steps of tumorigenesis (Table 1), highlighting their potential as a therapeutic target in cancer.

**Dependence receptors and clinical treatments**

**Targeting dependence receptor pathways: a promising avenue for cancer therapy**

In view of their multi-faceted role in the regulation of cancer hallmarks, DRs are emerging as very promising potential targets in oncology (Fig 3). Blocking interactions between these receptors and their ligands not only would trigger apoptotic death of cancer cells, but could also prevent metastatic spread, immune escape, and resistance to chemotherapy by inhibiting positive signaling from DRs responsible for EMT, stemness, angiogenesis, and immunomodulation. A lot of molecules targeting these receptors are being evaluated in clinical trials. Even though the dependence function has not directly been considered in most of these trials, results from some do highlight therapeutic potential. As discussed above, such molecules could have an impact on all step of tumorigenesis, from the tumor initiation to the metastatic dissemination.

We have seen that DRs can have an impact on stemness features in some cancer cells and that their activation supports the potential of tumor-initiating cells. Preventing their activation could therefore have a significant impact on post-treatment recurrence. For instance, Tarextumab, a Notch2/Notch3 monoclonal antibody, was shown to inhibit tumor growth and to decrease tumor-initiating cell frequency in preclinical studies. Unfortunately, the phase II clinical trial evaluating the efficacy of Tarextumab on metastatic pancreatic cancer (NCT01647828) did not show any improvement in patient survival (Hu et al., 2019), but its efficacy is still being tested for other cancer types (NCT01277146). Thus, targeting DRs may not only diminish cancer stem cell plasticity but potentially inhibit interactions between CSC and niche cells, including CAFs, thereby minimizing cancer recurrence if used in combination with conventional chemotherapies.

Since DRs can modulate early steps of the tumorigenesis process, targeting them could also be used as an innovative early-stage therapy, preventing key events that foster tumor growth such as angiogenesis. For instance, current clinical trials evaluate the combination of anti-angiogenic drugs and c-MET inhibitors to enhance anti-angiogenic killing of cancer cells, as exemplified by the combination of pazopanib and ARQ 197, also called tivantinib, a highly selective c-MET inhibitor, in renal cancer (NCT01468922). The same principle was followed in a clinical trial combining bevacizumab (Avastin), an anti-angiogenic drug already used in several cancer types and INC280, a highly potent and selective c-MET inhibitor (NCT02386826). Based on preclinical results demonstrating a synergistic effect between c-MET and VEGFR inhibitors in mice (Harshman & Choueiri, 2013; Cascone et al., 2017), these phase I clinical trials show the potential benefits of targeting c-MET, and more generally, DR-associated angiogenesis. Indeed, INC280 has already been approved by the United States FDA (Food and Drug Administration) for the treatment of NSCLC (East Hanover).

The impact of therapies targeting DRs on angiogenesis, such as the combinations described above, could also decrease metastatic spread. Since most DRs also have a direct impact on invasion and migration of cancer cells, their targeting could potentiate this anti-metastatic effect, for example, by preventing EMT. SAIT301, a humanized monoclonal antibody targeting the c-MET extracellular domain alpha chain, provides a good illustration of this potential. It was shown to provide significant benefit in a phase I trial (NCT02296879) and to reduce invasion and migration of nasopharyngeal cancer cells (Bhatia et al., 2017). Migration and invasion of cancer cells were also inhibited by another monoclonal antibody targeting c-MET, YYB-001 (Kim et al., 2019). A phase I clinical trial with this antibody has just been completed for colorectal cancer (NCT04368507) (Kim et al., 2020), reflecting the potential of therapies targeting DRs for preventing metastatic spread.

As discussed above, DRs have also been shown to modulate interactions between tumor and immune cells, usually promoting the ability of tumor cells to evade the immune system. Consequently, targeting them could be an innovative way to decrease immune resistance of cancer cells and enhance the efficiency of immune checkpoint inhibitors, when used in combination. DR antagonists could also be used as single therapies against hematopoietic cancer cells. For example, the anti-c-KIT antibody KTN0158 (also called CDX-0158) demonstrated a good efficacy against malignant mast cells in preclinical studies (London et al., 2012).
IL-10, TGF-β, immunomodulatory cytokines and transcriptional regulators such as Foxp3, within tumors. Mast cells activated by SCF participate in tumor immuno-suppression, increasing regulatory T cell number and enhancing the suppression of other T and NK cells in tumors, having a major pro-tumoral effect. This is the result of enhanced production of IL-17 and other inflammatory cytokines by SCF-stimulated mast cells. The presence of SCF-activated mast cells results in higher levels of immunomodulatory cytokines and transcriptional regulators such as IL-10, TGF-β, and Foxp3, within tumors (Huang et al., 2008). This study elegantly exemplifies how using drugs targeting DRs could enhance immunotherapy efficacy.

Finally, while DRs represent promising therapeutic targets in multiple cancer types, analysis of their expression could also enable the development of prognostic and/or predictive biomarkers in oncology. For example, Netrin-1 quantification in human fluids was shown to be a promising biomarker and a predictor of tumor recurrence in bladder, gastric, and lung cancers (Kefeli et al., 2012; Yıldırım et al., 2016; El-Gamal et al., 2020), and to correlates with poor prognosis in patients with brain metastasis (Harter et al., 2014). Another example is the quantification of c-MET expression, which provides predictive information on VEGFR tyrosine kinase inhibitor sensitivity in non-small-cell lung cancer (Cascone et al., 2017).

**Dependence receptors: how to target them efficiently**

We have seen that DRs are promising targets for therapy in oncology, firstly because of their implication throughout all phases in tumorigenesis and secondly, because this kind of drug would not only prevent these cancer-associated features but also lead to apoptosis in cancer cell harboring these receptors. We can then speculate that preventing these ligand-DR associations could be an efficient way of treating tumors. Nevertheless, since the DR concept is relatively new, it is important to discuss how pathways regulated by these proteins can be targeted most efficiently.

First, the decision of whether to target the ligand or its receptor has important implications, with several factors to be considered. For example, ligand availability and abundance, as well as the affinity of a ligand for its receptor and its binding dynamics, are critical variables to take into consideration (Kim & Cochran, 2017). A key parameter to consider for this strategy is the possible ligand pleiotropy. For example, Netrin-1 being a ligand for several DRs (DCC and UNC5 family receptors), targeting it offers an effective way to treat several types of cancers where one or several of its receptors is expressed. Conversely, SHH is a ligand for two DRs (PTCH-1 and CDON), but also acts through binding to several other non-DR receptors, suggesting that targeting only some of its receptors may allow a better control of subsequent biological effects. Moreover, the reported ability of some drugs targeting cell surface receptors to induce receptor downregulation, leading to a decreased presence of receptors at the membrane, should also be taken into consideration. Indeed, this phenomenon was reported to promote the therapeutic efficacy of a treatment with non-DR receptors (Kim & Cochran, 2017) but could decrease efficacy of treatments targeting DRs, since a diminution of their expression at the membrane would lead to decreased apoptotic signaling. Therapeutic targeting of DRs therefore requires careful consideration of the number of different ligands and receptors (DRs and non-DRs) involved, of the ligand bioavailability, and of the nature of downstream pathways implicated in a specific cancer type to achieve optimal efficiency.

Possible interactions between signaling pathways activated by different DRs may make their targeting more complex but could also reveal systems of cellular dependencies that are amenable to medical targeting. Ligand-dependent DR signaling seems to mostly coordinate the activity of a small number of signaling pathways (ERK/MAPK, PI3K/AKT, Wnt, or TGF-beta), implying that the net result of individual DR activation may vary depending on the cellular context of other similarly acting receptors. It is therefore plausible that the concomitant targeting of several of these DRs could have synergistic effects and may result in greater efficacy than the targeting of individual ones. Moreover, in view of the reported interaction and coordinated activation of similar signaling pathways by multiple DRs, targeting of several of these receptors concomitantly may preclude the emergence of resistance to drugs targeting single DRs. For example, targeting p75NTR could help bypass the observed resistance to tyrosine kinase inhibitors targeting TrkA or TrkC since it is involved in their regulation and seems to cooperate with them to induce several types of cellular responses (Barker & Shooter, 1994; Hantzopoulos et al., 1994; Jung et al., 2003).

Many existing drugs such as tyrosine kinase inhibitors in fact target DRs. Examples include the ALK and c-MET inhibitor Crizotinib, the c-KIT inhibitor Axitinib, as well as Entrectinib and Meresitinib, which inhibit Trk receptors. However, these molecules act on DRs without preventing ligand binding. When considering the DR paradigm, it is therefore clear that these drugs inhibit positive signaling pathways triggered by these receptors, but that they are not expected to mimic the effects of ligand withdrawal and therefore to actively trigger apoptotic pathways within cancer cells. We argue that, in the case of DRs, alternative targeting approaches that result in abrogation of receptor activation, while inducing pro-apoptotic signaling by the “ligand-starved” receptor, should provide much more significant therapeutic benefit. Such is the case for monoclonal antibodies that inhibit survival pathways triggered by these receptors by preventing binding of their ligands. Such molecules are currently being developed and tested such as ficlatuzumab (NCT03422536), KTN0158 (London et al., 2017)(NCT02642016), or NP137 (Cassier et al., 2019b) which, respectively, inhibit the binding between HGF and c-MET, SCF and c-KIT, or Netrin-1 and its receptors.

DRs responding to Netrin-1, particularly DCC and UNC5B, have been studied extensively in cancer, with validation of efficacy of a therapeutic molecule that inhibits interactions between Netrin-1 and its receptors in this context. For example, NP137, a humanized neutralizing monoclonal antibody against Netrin-1, is currently undergoing phase Ib/II clinical trials for the treatment of gynecological cancers (NCT04652076) and phase 1b trials in advanced or metastatic solid tumors (NCT02977195)(Cassier et al., 2019a). Interestingly, despite the involvement of Netrin-1 and its DRs in numerous pathways, no obvious toxicity has been observed in phase 1 trials (Cassier et al., 2019b).
Beyond their implication across multiple stages of tumorigenesis, DRs are also attractive targets because their mutation as well as the expression level of themselves and/or their ligands can predict sensitivity to their inhibitors. This opens the door for a precision oncology approach, whereby tumors that exhibit a high expression of DRs and their ligands may be eligible for treatment with relevant molecules targeting these receptor/ligand interactions. For instance, Larotrectinib (or LOXO-101), a drug which targets all three Trk receptors, is now approved for treatment of several types of cancer after several clinical trials (NCT02122913, NCT02637687, and NCT02576431) (Hong et al., 2020). This molecule was developed for the treatment of cancers carrying NTRK gene fusions, regardless of cancer type (Roviello et al., 2020). The use of Larotrectinib suggests that specific targeting of some DRs driven by improved molecular tumor profiling should allow better and more effective treatments for patients.

While DRs represent interesting targets for cancer therapy, additional information must be gathered to document potential side effects for this type of treatment. Because these receptors are generally expressed at low levels in adults, side effects of molecules targeting them may be low, as already shown for the anti-Netrin-1 antibody mentioned above. Nevertheless, considering their implication in neuronal development, a special attention should be paid to possible neurological side effects during development of these new drugs. It is also likely that cancer cell plasticity will enable the appearance of some degree of resistance to this type of treatment. This could, for example, occur via inhibition of pro-apoptotic signaling, for instance though repression of DAPK1 to disable UNC5B-dependent apoptotic signaling in the absence of ligand (Grandin et al., 2016).

**DRs: latest advances and translational impact**

Since the field of DR study is relatively new, recent and exciting discoveries in this area not only include additional mechanistic characterization of their role in various physio-pathological settings, but also include the novel identification of additional receptors that exhibit a DR function. Notably, Wang et al. recently observed that SCF withdrawal triggers apoptotic signaling through c-KIT intracellular cleavage by caspases, resulting in apoptosome activation (Wang et al., 2018). Considering the broadly reported involvement of c-KIT in several cancer types and in cancer stem cell regulation, this first identification of c-KIT as a DR should have important repercussions for researchers aiming to develop molecules targeting this receptor (Stankov et al., 2014; Abbaspour Babaei et al., 2016), since DR characteristics of c-KIT should be considered to fully exploit the therapeutic potential of this receptor.

Several elegant studies have also brought additional light on signaling mechanisms that drive the ligand-independent activation of apoptotic pathways by DRs, with the description of mitochondria permeabilization triggered by p40MET (Duplaquet et al., 2020), of EphB3 cleavage by Dral/FHL-2 and caspase-8 or 9 (Tsenkina et al., 2020), and of UNC5C cleavage by active δ-secretase all constituting important advances in the field. Findings from these studies not only further strengthen the concept of DR but also enable a better understanding of the DR signaling network, an essential step toward the rational design of new therapeutic molecules efficiently targeting these receptors. Along with these studies, the recent demonstration by Sumia et al. that homo- and heterodimerization of Kremen1 is required to trigger apoptotic signaling in the absence of Dickkopf1 binding and that the Kremen2 paralogue receptor can act as an inhibitor of Kremen1-induced cell death through direct competition with Kremen1, illustrates the underlying complexity of DR apoptotic signaling, and highlights an additional layer of DR regulation via direct interaction with neighboring transmembrane molecules.

Finally, an important recent development in the field has been the preclinical validation and clinical evaluation of NP137, a first-in-class monoclonal antibody targeting netrin-1 and the first molecule designed to fully exploit the therapeutic potential of a DR (Cassier et al., 2019b). Following promising data from a phase I clinical trial of NP137 as single agent in patients with advanced refractory solid tumors, this antibody is currently assessed in additional trials, including in combination with the anti-PD-1 antibody pembrolizumab for patients with locally advanced/metastatic uterine tumors (NCT04652076), known to exhibit frequent Netrin-1 overexpression. Beyond their direct impact on the survival of treated patients, results from these trials will represent an important step toward a better understanding of neutralizing monoclonal antibody as possible tools of choice to target DR, through the inhibition of ligand binding and the resulting activation of pro-apoptotic DR signaling.

**Conclusion**

We have sought here to define, explore, and analyze the concept of DRs and their implication in tumorigenesis. Indeed, through modulation of pathways such as ERK/MAPK or PI3K/AKT, activation of DRs influences tumorigenesis from initiation to metastasis. Altogether, studies involving DR pathways highlight the targeting of these receptors as an innovative and interesting approach for future cancer therapies. Indeed, preventing their activation could decrease the tumorigenic potential of cancer cells by limiting pro-tumoral features such as proliferation, angiogenesis, and/or chemoresistance, as well as by preventing ligand binding to induce apoptotic cell death.

Nevertheless, before accessing the full therapeutic potential of these receptors, a better understanding of the pathways they transduce within cancer cells and of their interactions, direct or indirect, is needed. Moreover, an important amount of preclinical and clinical studies is required to define what is the best way to target these receptors for which tumor type and to further characterize potential side effects. These studies represent an essential step toward unraveling the real potential of dependence receptor targeting for the benefit of cancer patients.
Acknowledgements

FH and PM wish to acknowledge the support of INSERM and the University of Melbourne (LIA2018) "Targeting cancer cell plasticity and self-renewal to personalize cancer treatment" funded project. MB receives a scholarship under the University of Melbourne-CNRS Network (MCN2020) program. FH is supported by the NHMRC of Australia (Grant 1164081). MG gratefully acknowledges support from the John Landers Fellowship.

Conflict of interest

Patrick Mehlen and Agnès Bernet are shareholders of Netris Pharma, which develops a netrin-1 antibody for clinical use. The other authors declare no conflict of interest.

For more information

i F. Hollandie lab: https://mdhs.unimelb.edu.au/centre-for-cancer-research/our-research/Tumour-Heterogeneity-in-Metastatic-Cancer

ii P. Mehlen lab: https://www.crl.fr/en/teri-department/apoptose-cancer-et-developpement/

References

Abbaspour Babaei M, Kamalideghban B, Saleem M, Huri HZ, Ahmadipour F (2016) Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des Devel Ther 10: 2443–2459

Arakawa H (2004) Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer 4: 978–987

Barker PA, Shooter EM (2016) A novel mechanism for Hirschsprung disease. Trends Pharmacol Sci 37: 201–209

Bhatia S, Monkman J, Toh AKL, Nagaraj SH, Thompson EW (2013) Met tyrosine kinase receptor. Cancer Drug Des Dev Ther 7: 439–443

Bhutkar A, Ay A, Al A, Yuce K, Ayhan A (2003) Overexpression of the c-Met/IGF receptor and its prognostic significance in uterine cervix carcinomas. Gynecol Oncol 88: 123–129

Bernet A, Mazelin L, Coissieux MM, Gadot N, Ackerman SL, Scoazec JY, Bhatia S, Monkman J, Toh AKL, Nagaraj SH, Thompson EW (2013) Met tyrosine kinase receptor. Cancer Drug Des Dev Ther 7: 439–443

Cascone T, Xu LI, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB et al (2017) The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res 23: 5489–5501

Cassier P, Eberst L, Garin G, Courbebaisse Y, Terret C, Robert M, Frenel J-S, Depil S, Delord J-P, Perol D et al (2019a) A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. Ann Oncol 30: v159

Cassier P, Eberst L, Garin G, Courbebaisse Y, Terret C, Robert M, Frenel J-S, Depil S, Delord J-P, Perol D et al (2019b) A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. Ann Oncol 30: v159

Causseret F, Sumia I, Pierani A (2016) Kremen1 and Dickkopf1 control cell survival in a Wnt-independent manner. Cell Death Differ 23: 323–332

Chen G, Kang SS, Wang Z, Ahn EH, Xiu Y, Liu X, Sandool AM, Manfredson FP, Zhang Z, Ye K (2021) Netrin-1 receptor UNC5C cleavage by active 6'-secretase enhances neurodegeneration, promoting Alzheimer’s disease pathologies. Sci Adv 7: eabe4499

De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C (2011) Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 103: 645–661

Delloye-Bourgeois C, Gibert B, Rama N, Delcros J-G, Gadot N, Scoazec J-Y, Krauss R, Bernet A, Mehlen P (2013) Sonic hedgehog promotes tumor cell survival by inhibiting CDON pro-apoptotic activity. PloS Biol 11: e1001623

Di Paolo D, Ambrogio C, Pastinorio F, Brighone C, Martinengo C, Carosio R, Loi M, Pagnan G, Emionite L, Cilli M et al (2011) Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther 19: 2201–2212

Duplaquet L, Leroy C, Vincent A, Paget S, Lefebvre J, Vanden Abeele F, Lancel S, Giffard F, Paumelle R, Bidaux G et al (2020) Control of cell death/survival balance by the MET dependence receptor. Elife 9: e50041

East Hanoverer. N Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METEx14

El-Gamal R, Mohktar N, Ali-El-Dein B, Baiomy AA, Aboazma SM (2020) Netrin-1: a new promising diagnostic marker for muscle invasion in bladder cancer. Urol Oncol: Semin Origin Invest 38: 640.e641–640.e612

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759–767

Fernandez M, Duplaquet L, Tulisane D (2019) Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase. Biochem J 474: 3269–3306

Forrest CM, McNair K, Vincenten MCJ, Darlington LG, Stone TW (2007) MET tyrosine kinase receptor. Cancer Drug Des Dev Ther 1: 127–129

Forest CM, McNair K, Vincenten MCJ, Darlington LG, Stone TW (2016) Selective depletion of tumour suppressors Deleted in Colorectal Cancer (DCC) and neogenin by environmental and endogenous serine proteases: linking diet and cancer. BMC Cancer 16: 772

Foveau B, Leroy C, Ancot F, Deheuninck J, Ji Z, Faveur V, Tulisane D (2007) Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor. Cell Death Differ 14: 752–764

Furne C, Ricard J, Cabrera JR, Pays L, Bethea JR, Mehlen P, Liebl DJ (2009) EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis. Biochim Biophys Acta 1793: 231–238

© 2021 The Authors

EMBO Molecular Medicine 13: e14495 | 2021
Garton AJ, Seibel S, Lopresti-Morrow L, Crew L, Janson N, Mandiyan S, Trombetta ES, Pankratz S, LaVallee TM, Gerdich R (2017) Anti-KIT monoclonal antibody treatment enhances the antitumor activity of immune checkpoint inhibitors by reversing tumor-induced immunosuppression. *Mol Cancer Ther* 16: 671–680

Grandin M, Mathot P, Devailli G, Bidet Y, Ghanotis A, Favor C, Gibert B, Gadot N, Puisieux I, Herceg Z et al (2016) Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference. *EMBO Mol Med* 8: 863–877

Han Q, Han F, Fan Y, Lian B, Xiao J, Sun W, Han D, Kou H, Li C, Wu B (2020) Notch3 is involved in the proliferation of renal cancer cells via regulation of cell cycle progression and HIF-2α. *Oncol Lett* 20: 379

Hantzopoulos PA, Suri C, Glass DJ, Goldfarb MP, Yancopoulos GD (2014) Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach Harter PN, Zinke J, Scholz A, Thich J, Zachskorn C, Kvasnicka HM, Goeppert B, Han Q, Han F, Fan Y, Lian B, Xiao J, Sun W, Han D, Kou H, Li C, Wu B (2019) Notch3 is involved in the proliferation of renal cancer cells via regulation of cell cycle progression and HIF-2α. *Oncol Lett* 20: 379

Huang BO, Lei Z, Zhang G-M, Li D, Song C, Li BO, Liu Y, Yuan YE, Unkeless J, Sanchez J, Sohal DPS (2012) Anti-KIT receptor to suppress TGF-β signaling in breast cancer. *Oncol Lett* 3: 97–101

Huang H and DCC. *Mol Cell* 8: 6870–6875

Jin W, Yun C, Kwak MK, Kim TA, Kim SJ (2007) TrkC binds to the type II TGF-β receptor to suppress TGF-β signaling. *Oncogene* 26: 7684–7691

Jones C, Rodriguez-Pinilla M, Labrosos M, Bax D, Messahel B, Vujanic GM, Reis-Filho JS, Pritchard-Jones K (2007) c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours. *J Clin Pathol* 60: 1226–1231

Jung K-M, Tan S, Landman N, Petrova K, Murray S, Lewis R, Kim PK, Kim DS, Ryu SH, Chao MV et al (2003) Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. *J Biol Chem* 278: 42161–42169

Kang HC, Wakabayashi Y, Jen K-Y, Mao J-H, Zoumpourlis V, Del Rosario R, Balmian A (2013) Ptch1 overexpression drives skin carcinogenesis and developmental defects in K14PtchFVB mice. *J Invest Dermatol* 133: 1311–1320

Kefeli U, Uncuncu Kefeli A, Cabak D, Isik U, Sonkaya A, Acikgoz O, Ozden E, Uygur K (2017) Netrin-1 in cancer: potential biomarker and therapeutic target? *Tum Biol* 39: 1010428317698388

Kefeli U, Yildirim ME, Aydin D, Madenci OC, Yasar N, Sener N, Mert AG, Yuksel S, Ercelpe OB, Korkmaz T et al (2012) Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment. *Biomarkers* 17: 663–667

Kim HJ, Lee S, Oh Y-S, Chang HK, Kim YS, Hong SH, Kim JY, Park Y-W, Lee S-J, Song S-W et al (2019) Humanized anti-hepatic growth factor monoclonal antibody (YYB-101) inhibits ovarian cancer progression. *Front Oncol* 9: 571

Kim JW, Cochran JR (2017) Targeting ligand-receptor interactions for development of cancer therapeutics. *Curr Opin Chem Biol* 38: 62–69

Kim ST, Hong JY, Park SH, Park JO, Park YW, Park N, Lee H, Hong SH, Lee S-J, Song S-W et al (2020) First-in-human phase I trial of anti-hepatic growth factor antibody (YyB101) in refractory solid tumor patients. *Ther Adv Med Oncol* 12: 1758835920926796

Kimura Y, Ding B, Imai N, Nolan DJ, Butler JM, Rafi S (2011) c-KIT-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. *PLoS One* 6: e26918

Kong C, Zhan B, Piao C, Zhang Z, Zhu Y, Li Q (2016) Overexpression of UNC5B in bladder cancer cells inhibits proliferation and reduces the volume of transplantation tumors in nude mice. *BMC Cancer* 16: 892

Lerner-Marmaroosh N, Miralem T, Gibbs PEM, Maines MD (2008) Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling. *Proc Natl Acad Sci USA* 105: 6870–6875

Ley S, Weigert A, Weichand B, Henke N, Mille-Baker B, Janssen RAJ, Brüne B (2013) The role of TRKA signaling in IL-10 production by apoptotic tumor cell-activated macrophages. *Oncogene* 32: 631–640

Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM (2011a) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. *Gastroenterology* 141: 2218–2227

Li Y, Li A, Glass M, Lal B, Ying M, Sang Y, Xia S, Tragesser D, Guerrero-Cazares H, Eberhart CG et al (2011b) c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. *Proc Natl Acad Sci USA* 108: 9951–9956

Lin C, Ren Z, Yang Xi, Yang R, Chen Y, Liu Z, Dai Z, Zhang YU, He Y, Zhang C et al (2020) Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMF and confers resistance to the EGFR inhibitor erlotinib. *Cancer Lett* 472: 81–96

Liu C, Liu L, Chen X, Cheng J, Zhang H, Zhang C, Shan J, Shen J, Qian C (2018) LSD1 stimulates cancer-associated fibroblasts to drive Notch3-dependent self-renewal of liver cancer stem-like cells. *Can Res* 78: 938–949

Liu F, Song S, Yi Z, Zhang M, Li J, Yang F, Yin H, Yu X, Guan C, Liu Y et al (2017) HGF induces EMT in non-small-cell lung cancer through the hBVR pathway. *Eur J Pharmacol* 811: 180–190

Lliambi F, Causet F, Bloch-Gallego E, Mehlen P (2001) Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. *EMBO* 20: 3721–3722

Lliambi F, Loureinho FC, Gozuacik D, Guix C, Pays L, Del Rio G, Kimchii A, Mehlen P (2005) The dependence receptor UNC5H2 mediates apoptosis through DAP-kinase. *EMBO* 24: 1192–1201
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM et al (2017) KTN105B, a humanized anti-KIT monoclonal antibody, demonstrates biologic activity against both normal and malignant canine mast cells. Clin Cancer Res 23: 2565–2574

Louie E, Chen XF, Coomes A, Ji K, Tsirka S, Chen EI (2017) Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 32: 4064–4077

Luchino J, Hocine M, Amoureux M-C, Gibert B, Bernet A, Royet A, Treilleux I, Lécine P, Borg J-P, Mehlen P et al (2013) Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. Cancer Cell 24: 673–685

Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, Lutterbaugh JD, Mehlen P, Guenebeaud C, Mille F, Llambi F, Guix C, Delloye-Bourgeois C, Guenebeaud C, Castro-Mori M, Mahoney JE, Stupnikov MR, Paez-Cortez JR, Szymaniak AD, Varelas X, Negulescu A-M, Mehlen P (2013) Role of angiogenesis in drug resistance. Mol Cancer 12: 151

Mehlen P, Guenebeaud C (2010) Netrin-1 and its dependence receptors as original targets for cancer therapy. Curr Opin Oncol 22: 46–54

Mille F, Llambi F, Guix C, Delloye-Bourgeois C, Guenebeaud C, Castro-Olbregon S, Brederes DE, Thibert C, Mehlen P (2009) Interfering with multimerization of netrin-1 receptors triggers tumor cell death. Cell Death Differ 16: 1344–1351

Mirakaj V, Jennewein C, König K, Granja T, Rosenberger PG (2012) The guidance receptor neogenin promotes pulmonary inflammation during lung injury. FASEB J 26: 1549–1558

Mori M, Mahoney JE, Stupnikov MR, Paez-Cortez JR, Szymaniak AD, Varelas X, Herrick DB, Schwob J, Zhang H, Cardoso WV (2015) Notch3/jagged signaling controls the pool of undifferentiated airway progenitors. Development 142: 258–267

Mourali J, Bénard A, Lourenço CF, Monnet Céline, Greenland C, Moog-Lutz C, Racaud-Sultan C, Gonzalez-Dunia D, Vigny M, Mehlen P et al (2006) Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 26: 6209–6222

Navab R, Liu J, Seiden-Long I, Shih W, Li M, Bardarchi B, Chen Y, Lau D, Zu Y-F, Cescon D et al (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11: 1292–1300

Negulescu A-M, Mehlen P (2018) Dependence receptors – the dark side of self-renewal. Stem Cells 27: 408–419

Nikoletopoulou V, Lickert H, Frade JM, Rencurel C, Giallonardo P, Zhang L, Bibel M, Barde Y-A (2010) Neurotrophin receptors TrkB and TrkC cause neuronal death whereas TrkB does not. Nature 467: 59–63

Ogunwobi OO, Puszyn W, Dong H-J, Liu C (2013) Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One 8: e63785

Park JT, Chen X, Tropè CG, Davidson B, Shih I-M, Wang T-L (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177: 1087–1094

Park JT, Li M, Nakayama K, Mao T-L, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih I-M, Wang T-L (2006) Notch3 Gene amplification in ovarian cancer. Can Res 66: 6312–6318

Prager BC, Xie Q, Bao S, Rich JN (2019) Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24: 41 – 53

Prasetyanti PR, Medema JP (2017) Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer 16: 41

Ribazadeh S, Oh J, Zhong LT, Yang J, Bitler CM, Butcher LL, Bredesen DE (1993) Induction of apoptosis by the low-affinity NGF receptor. Science 261: 345 – 348

Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X (2010) Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer 9: 157

Roviello G, D’Angelo A, Scirrotto M, Mini E, Nobili S, De Logu F, Massi D (2020) TRK fusion positive cancers: from first clinical data of a TRK inhibitor to future directions. Crit Rev Oncol Hematol 152: 103011

Stankov K, Popovic S, Mikov M (2014) C-KIT signaling in cancer treatment. Curr Pharm Des 20: 2849–2880

Stupack DG (2005) Integrins as a distinct subtype of dependence receptors. Cell Death Differ 12: 1021–1030

Stupack DG, Puente XS, Boutsaboualpy S, Stoggard CM, Cheresu DA (2001) Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 155: 459–470

Sumia I, Pianeri A, Causeret F, Neves D, Chen H-W, Bernard D, Yang P-C, Bernet A et al (2019) Cancer-associated fibroblasts produce netrin-1 to control cancer cell plasticity. Cancer Cell 39: 3651–3661

Svardova E, Vesela B, Tucker AS, Matalova E (2018) Activation of pro-apoptotic caspases in non-apoptotic cells during odontogenesis and related osteogenesis. Front Physiol 9: 174

Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Akagi M, Ellis LM (2002) Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9: 610 – 616

Thibert C, Teillet MA, Lapointe F, Mazelin L, Le Douarin NM, Mehlen P (2003) Inhibition of neuroepithelial patched-induced apoptosis by sonic hedgehog. Science 301: 843 – 846

Thiébaut K, Mazelin M, Pays L, Llambi F, Joly M-O, Scoazec J-Y, Saurin J-C, Romeo G, Mehlen P (2003) The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment. Proc Natl Acad Sci USA 100: 4173–4178

Tokiya Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Takanaka M, Mohri Y, Inoue Y, Goel A, Kusunoki M (2012) Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 130: 2912–2921

Tsengkina Y, Ricard J, Runko E, Quijala- Acosta MM, Mier J, Liebl DJ (2015) EphB3 receptors function as dependence receptors to mediate
and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. *Exp Cell Res* 371: 63–71

Yildirim ME, Kefeli U, Aydin D, Sener N, Gümüş M (2016) The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker. *Tumor Biol* 37: 11903–11907

Yong L-K, Lai S, Liang Z, Poteet E, Chen F, van Buren G, Fisher W, Mo Q, Chen C, Yao Q (2016) Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival. *Oncotarget* 7: 87431–87448

Zhang J, Guo L, Liu X, Li W, Ying J (2017) MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma. *Oncotarget* 8: 10264–10273

Zhang X, Cui P, Ding B, Guo Y, Han K, Li J, Chen H, Zhang W (2018) Netrin-1 elicits metastatic potential of non-small cell lung carcinoma cell by enhancing cell invasion, migration and vasculogenic mimicry via EMT induction. *Cancer Gene Ther* 25: 18–26

Zhou X, Hao Q, Liao P, Luo S, Zhang M, Hu G, Liu H, Zhang Y, Cao BO, Baddoo M et al (2016) Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator *Elf5*: e15099

Zhu Y, Li Y, Haraguchi S, Yu M, Ohira M, Ozaki T, Nakagawa A, Ushijima T, Isogai E, Kosaki H et al (2013) Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression. *J Clin Invest* 123: 2935–2947

Zhu Y, Li Y, Nakagawara A (2021) UNC5D dependence receptor family in human cancer: a controllable double-edged sword. *Cancer Lett* 516: 28–35

Zuazo-Castelu I, Casanovas O (2018) Unraveling the role of angiogenesis in cancer ecosystems. *Front Oncol* 8: 248

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.